Compass Therapeutics (NASDAQ:CMPX) Earns "Buy" Rating from D. Boral Capital

Compass Therapeutics (NASDAQ:CMPX - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $32.00 price objective on the stock.

A number of other brokerages also recently commented on CMPX. Jefferies Financial Group increased their price target on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, February 10th. HC Wainwright lifted their target price on Compass Therapeutics from $10.00 to $24.00 and gave the stock a "buy" rating in a research note on Friday, April 4th. Leerink Partnrs upgraded shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. Piper Sandler initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price objective on the stock. Finally, Leerink Partners upgraded shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and boosted their target price for the company from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $13.38.

Compass Therapeutics Trading Down 8.5 %

Compass Therapeutics stock traded down $0.18 during midday trading on Monday, reaching $1.94. The stock had a trading volume of 877,992 shares, compared to its average volume of 874,372. The company has a fifty day moving average price of $2.23 and a two-hundred day moving average price of $2.10. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $4.08. The company has a market capitalization of $268.27 million, a P/E ratio of -5.24 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, equities research analysts predict that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Compass Therapeutics

In related news, insider Jonathan Anderman purchased 20,000 shares of the business's stock in a transaction on Monday, April 7th. The stock was acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the purchase, the insider now directly owns 21,000 shares in the company, valued at approximately $32,340. This represents a 2,000.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the firm's stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. Insiders own 28.50% of the company's stock.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors have recently modified their holdings of the company. MPM Bioimpact LLC boosted its stake in Compass Therapeutics by 51.9% in the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after buying an additional 2,926,002 shares in the last quarter. Enavate Sciences GP LLC purchased a new position in Compass Therapeutics in the 4th quarter worth $11,293,000. Tang Capital Management LLC raised its position in Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after purchasing an additional 4,087,005 shares during the period. Rock Springs Capital Management LP lifted its stake in Compass Therapeutics by 2.7% in the fourth quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company's stock worth $8,380,000 after purchasing an additional 150,336 shares during the last quarter. Finally, Blue Owl Capital Holdings LP boosted its position in Compass Therapeutics by 2.6% during the fourth quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company's stock valued at $4,284,000 after buying an additional 75,000 shares during the period. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.